title: [Peroxisome proliferator-activated receptor (PPAR) gamma: a new target for the treatment of inflammatory bowel disease].
abstract: The peroxisome proliferator-activated receptor (PPAR) gamma is highly expressed in the colon mucosa. In vitro, it regulates inflammation.
  
  
  OBJECTIVE
  To evaluate the anti-inflammatory functions of PPARgamma agonist during a trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice.
  
  
  METHODS
  Colitis was induced in Balb/c mice after intra-rectal administration of TNBS. The intensity of inflammation was assessed 2 and 5 days after colitis induction by macroscopic and histologic scores and by the quantification of colon myeloperoxidase (MPO), IL-1B and TNFalpha mRNA concentrations. The therapeutic role of PPARgamma agonist given by oral gavage was assessed in preventive and treatment modes.
  
  
  RESULTS
  TNBS induced severe macroscopic and histologic lesions, with high mucosal MPO, IL-1B and TNFalpha mRNA concentrations. PPARgamma agonist given preventively or in treatment mode allowed a significant decrease of macroscopic and histologic scores through a normalization of MPO, IL-1B and TNFalpha mRNA concentrations.
  
  
  CONCLUSIONS
  PPARgamma agonist decreases the intensity of TNBS induced colitis through normalization of IL-1B and TNFalpha expression. PPARgamma agonists may be proposed as new therapeutic agents in inflammatory bowel diseases.
authors.affiliation: Laboratoire de Recherche sur les Maladies Inflammatoires Intestinales (CRI4U0048), CHU Lille.
authors.forename: L
authors.initials: L
authors.lastname: Dubuquoy
authors.forename: C
authors.initials: C
authors.lastname: Bourdon
authors.forename: M
authors.initials: M
authors.lastname: Peuchmaur
authors.forename: M D
authors.initials: MD
authors.lastname: Leibowitz
authors.forename: S
authors.initials: S
authors.lastname: Nutten
authors.forename: J F
authors.initials: JF
authors.lastname: Colombel
authors.forename: J
authors.initials: J
authors.lastname: Auwerx
authors.forename: P
authors.initials: P
authors.lastname: Desreumaux
mesh_terms: D000818:Animals; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D003106:Colon / Q000201:enzymology; D007375:Interleukin-1 / Q000235:genetics; D007413:Intestinal Mucosa / Q000201:enzymology; D051379:Mice; D008807:Mice, Inbred BALB C; D009195:Peroxidase / Q000032:analysis / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists* / Q000502:physiology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014157:Transcription Factors / Q000819:agonists* / Q000502:physiology; D014302:Trinitrobenzenesulfonic Acid; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
chemical_list: D007375:Interleukin-1; D012333:RNA, Messenger; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D014409:Tumor Necrosis Factor-alpha; D014302:Trinitrobenzenesulfonic Acid; D009195:Peroxidase